This is a a Real world, Prospective, Observational Multicenter Study to Monitor the Routine Clinical Use of Pegylated Erythropoetin (PegEPO) in the Treatment of Anemia due to Chronic Kidney Disease.
Not Applicable
- Conditions
- Health Condition 1: N189- Chronic kidney disease, unspecified
- Registration Number
- CTRI/2024/04/065689
- Lead Sponsor
- Apex Kidney Care Pvt. Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
(1.) Greater than 18 years
(2.) CKD patients stage IV-V (Non Dialysis) and Maintenance Haemodialysis patients (greater or equal to 3 months), Both ESA naïve and switchover patients from other ESAs.
(3.) Patients on rEPO/ DPO with stable dosing for 3 months.
(4.) Hb- 7 to 10g/dl.
(5.) Tsat %: greater than 20%.
(6.) Ferritin greater than 100 mcg/l
Exclusion Criteria
(1.) Any patient who does not fit the inclusion criteria as per physician’s opinion or not fit for PegEPO therapy as per PI.
(2.) Patient with a history of hypersensitivity reactions or contraindication to the excipients of Peg EPO.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method